BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25220591)

  • 21. Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.
    Kwiatkowska A; Couture F; Levesque C; Ly K; Desjardins R; Beauchemin S; Prahl A; Lammek B; Neugebauer W; Dory YL; Day R
    J Med Chem; 2014 Jan; 57(1):98-109. PubMed ID: 24350995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
    Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.
    Kwiatkowska A; Couture F; Levesque C; Ly K; Beauchemin S; Desjardins R; Neugebauer W; Dory YL; Day R
    ChemMedChem; 2016 Feb; 11(3):289-301. PubMed ID: 26751825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.
    Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z
    J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
    J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.
    Dianati V; Navals P; Couture F; Desjardins R; Dame A; Kwiatkowska A; Day R; Dory YL
    J Med Chem; 2018 Dec; 61(24):11250-11260. PubMed ID: 30501188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
    Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
    Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
    Liu Y; Hu X; Liu H; Bu L; Ma X; Cheng K; Li J; Tian M; Zhang H; Cheng Z
    J Nucl Med; 2013 Dec; 54(12):2132-8. PubMed ID: 24198391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
    Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.
    Levesque C; Fugère M; Kwiatkowska A; Couture F; Desjardins R; Routhier S; Moussette P; Prahl A; Lammek B; Appel JR; Houghten RA; D'Anjou F; Dory YL; Neugebauer W; Day R
    J Med Chem; 2012 Dec; 55(23):10501-11. PubMed ID: 23126600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection.
    Hao G; Zhou J; Guo Y; Long MA; Anthony T; Stanfield J; Hsieh JT; Sun X
    Amino Acids; 2011 Nov; 41(5):1093-101. PubMed ID: 20221650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
    Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
    Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
    Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
    Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.
    Cai H; Wu JS; Muzik O; Hsieh JT; Lee RJ; Peng F
    J Nucl Med; 2014 Apr; 55(4):622-8. PubMed ID: 24639459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolically Stabilized (68)Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon.
    Richter S; Wuest M; Bergman CN; Krieger S; Rogers BE; Wuest F
    Mol Pharm; 2016 Apr; 13(4):1347-57. PubMed ID: 26973098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
    Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
    J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.